SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 2176420

Cover Image

PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 2176420

Digital Biomarkers for Neurological Disorders Market Forecasts to 2034 - Global Analysis By Biomarker Type, Neurological Disorder, Technology Platform, Clinical Application, End User and By Geography

PUBLISHED:
PAGES: 300+ Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4150
PDF (2-5 User License)
USD 5250
PDF & Excel (Site License)
USD 6350
PDF & Excel (Global Site License)
USD 7500

Add to Cart

According to Stratistics MRC, the Global Digital Biomarkers for Neurological Disorders Market is estimated at $2.6 billion in 2026 and is expected to reach $10.1 billion by 2034, growing at a CAGR of 18.5% during the forecast period. Digital Biomarkers for Neurological Disorders utilize wearable sensors, smartphone applications, digital cognitive assessments, and artificial intelligence to measure neurological functions and disease-related changes. Increasing prevalence of neurological disorders, growing demand for early diagnosis, and rising adoption of remote patient monitoring are driving market growth. Technological advancements in speech analysis, movement tracking, eye-tracking, and multimodal analytics are improving neurological assessment capabilities. Growing investment in precision neurology, decentralized clinical trials, and personalized treatment monitoring is creating opportunities across healthcare providers, pharmaceutical companies, and research institutions.

Market Dynamics:

Driver:

Increasing neurological disease prevalence and demand for objective disease monitoring

Increasing neurological disease prevalence and demand for objective disease monitoring are driving adoption of digital biomarkers. Healthcare providers increasingly utilize wearable sensors, cognitive assessment applications, and movement monitoring technologies to evaluate neurological functions. Digital biomarkers support continuous symptom assessment, early identification of disease progression, and personalized treatment decisions. Aging populations, increasing dementia and Parkinson's disease prevalence, and expanding neurological research encourage adoption. Advances in artificial intelligence, connected devices, and remote monitoring platforms further strengthen market development.

Restraint:

Limited clinical validation and challenges in digital biomarker standardization

Limited clinical validation and challenges in digital biomarker standardization restrain adoption across neurological healthcare. Digital biomarker technologies require extensive validation to demonstrate accuracy, reliability, and clinical relevance across diverse patient populations. Differences in sensor performance, assessment protocols, and analytical methodologies complicate comparison between platforms. Regulatory uncertainty, limited reimbursement frameworks, and difficulties integrating digital assessments into clinical workflows create additional barriers. Healthcare organizations may hesitate to adopt technologies lacking established clinical evidence and standardized interpretation guidelines.

Opportunity:

Expansion of AI-enabled neurological assessment and decentralized clinical trials

Expansion of AI-enabled neurological assessment and decentralized clinical trials presents significant growth opportunities. Advanced digital biomarker platforms combine wearable sensing, speech analytics, cognitive testing, and machine learning to assess neurological changes continuously. Integration with remote monitoring systems enables personalized treatment evaluation and longitudinal disease tracking. Pharmaceutical companies increasingly explore digital endpoints to improve clinical trial efficiency and patient participation. Growing investment in precision neurology, early disease detection, and multimodal assessment encourages innovation and commercialization.

Threat:

Patient data privacy concerns and competition from conventional neurological assessments

Patient data privacy concerns and competition from conventional neurological assessments pose significant challenges to digital biomarker technologies. Continuous collection of behavioral, cognitive, and physiological information creates cybersecurity and confidentiality risks. Inaccurate algorithmic interpretations or inconsistent sensor measurements may affect clinical confidence and treatment decisions. Established neurological examinations, neuroimaging, and laboratory diagnostics remain important competing assessment methods. Increasing regulatory scrutiny, evolving data protection requirements, and demands for transparent clinical evidence compel developers to maintain secure and reliable platforms.

Covid-19 Impact:

The COVID-19 pandemic accelerated interest in remote neurological assessment, digital health technologies, and decentralized clinical research. Healthcare organizations increasingly explored smartphone-based cognitive testing, wearable movement monitoring, and remote neurological evaluation to reduce unnecessary clinical visits. Pharmaceutical companies expanded digital data collection to support clinical trial continuity. However, disruptions to research activities and healthcare services affected some development programs. Subsequent investment in telehealth, remote patient monitoring, and digital clinical endpoints continues to support market development.

The cognitive & neuropsychological biomarkers segment is expected to be the largest during the forecast period

The cognitive & neuropsychological biomarkers segment is expected to account for the largest market share during the forecast period due to increasing demand for objective cognitive assessment and early identification of neurological decline. Digital cognitive testing platforms evaluate memory, attention, executive function, and other neurological capabilities. Growing Alzheimer's disease prevalence, increasing dementia screening initiatives, and expanding cognitive research encourage adoption. Integration with artificial intelligence and remote assessment a technology supports longitudinal monitoring and personalized neurological care across clinical and research environments.

The multimodal digital biomarkers segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the multimodal digital biomarkers segment is predicted to witness the highest growth rate due to increasing demand for comprehensive neurological assessment. These platforms integrate cognitive, movement, speech, eye-tracking, and physiological data to characterize neurological conditions more effectively. Advances in machine learning, wearable sensors, and connected monitoring technologies improve analytical capabilities. Growing investment in precision neurology, digital clinical endpoints, and personalized disease management is expected to accelerate adoption across healthcare and pharmaceutical research.

Region with largest share:

During the forecast period, North America is expected to hold the largest share due to advanced healthcare infrastructure, substantial investment in digital health technologies, and extensive neurological research activities. The United States leads regional development through biotechnology companies, research institutions, and healthcare organizations developing digital neurological assessment platforms. Increasing neurological disease prevalence, established clinical trial infrastructure, and demand for personalized healthcare encourage adoption. Venture capital investment and partnerships between technology developers and pharmaceutical companies strengthen commercialization.

Region with highest CAGR:

Over the forecast period, Asia Pacific is anticipated to exhibit the highest CAGR, supported by expanding healthcare infrastructure, aging populations, and increasing investment in digital health technologies. China, India, Japan, South Korea, and Australia are advancing neurological research, remote assessment platforms, and AI-enabled healthcare applications. Growing dementia prevalence, improving access to specialized healthcare, and increasing adoption of connected devices encourage development. Government digital health initiatives and collaborations between research institutions and technology companies support regional growth.

Key players in the market

Some of the key players in the Digital Biomarkers for Neurological Disorders Market include Koneksa Health, Inc., Altoida, Inc., Linus Health, Inc., Rune Labs, Inc., NeuraLight Ltd., NeuraMetrix, Inc., Neurotrack Technologies, Inc., Cambridge Cognition Holdings plc, Cogstate Ltd., IXICO plc, Aural Analytics, Inc., Sonde Health, Inc., BioSensics LLC, Empatica Inc., Cumulus Neuroscience Ltd., Beacon Biosignals, Inc., Huma Therapeutics Limited, and F. Hoffmann-La Roche Ltd.

Key Developments:

In September 2026, Altoida, Inc. announced a collaboration with Circular Genomics to combine blood-based circular RNA biomarkers with its AI-powered Digital NeuroMarker platform. The partnership aims to improve early Alzheimer's disease identification, patient stratification, and longitudinal monitoring by integrating biological indicators with objective digital cognitive assessments.

In September 2026, Koneksa Health, Inc. announced positive topline results from its KH007 observational study evaluating digital measures of Parkinson's disease progression. The study met its primary participant compliance endpoint, supporting the feasibility of longitudinal digital assessments involving motor and speech measurements in neurological clinical research.

In July 2026, Linus Health, Inc. presented new research at the Alzheimer's Association International Conference highlighting digital cognitive assessment approaches for earlier disease detection and more informed clinical evaluation. The findings support the expanding role of AI-enabled digital biomarkers in cognitive screening, diagnostic workflows, and patient-centered neurological assessment.

Biomarker Types Covered:

  • Cognitive & Neuropsychological Biomarkers
  • Motor Function & Movement Biomarkers
  • Speech & Voice Biomarkers
  • Oculomotor & Eye Movement Biomarkers
  • Neurophysiological Biomarkers
  • Sleep & Circadian Rhythm Biomarkers
  • Digital Behavioral Biomarkers
  • Multimodal Digital Biomarkers
  • Other Biomarker Types

Neurological Disorders Covered:

  • Alzheimer's Disease & Other Dementias
  • Parkinson's Disease & Movement Disorders
  • Multiple Sclerosis
  • Epilepsy & Seizure Disorders
  • Stroke & Cerebrovascular Disorders
  • Amyotrophic Lateral Sclerosis (ALS)
  • Huntington's Disease
  • Traumatic Brain Injury
  • Other Neurological Disorders

Technology Platforms Covered:

  • Wearable Sensor-Based Platforms
  • Smartphone & Mobile Application-Based Platforms
  • Digital Cognitive Assessment Platforms
  • Speech & Voice Analysis Platforms
  • Eye-Tracking & Computer Vision Platforms
  • EEG & Neurophysiological Monitoring Platforms
  • Multimodal AI & Digital Biomarker Analytics Platforms
  • Other Technology Platforms

Clinical Applications Covered:

  • Early Disease Detection & Screening
  • Diagnostic Assessment & Clinical Decision Support
  • Disease Progression Monitoring
  • Symptom Severity & Functional Assessment
  • Treatment Response & Therapeutic Monitoring
  • Predictive & Prognostic Assessment
  • Clinical Trial Digital Endpoints
  • Remote Neurological Patient Monitoring
  • Other Clinical Applications

End Users Covered:

  • Hospitals & Health Systems
  • Neurology & Specialty Clinics
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Academic Medical Centers & Research Institutions
  • Home Healthcare & Remote Monitoring Providers
  • Diagnostic & Cognitive Assessment Centers
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
      • Saudi Arabia
      • United Arab Emirates
      • Qatar
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • Egypt
      • Morocco
      • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Product Code: SMRC40922

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Digital Biomarkers for Neurological Disorders Market, By Biomarker Type

  • 5.1 Cognitive & Neuropsychological Biomarkers
  • 5.2 Motor Function & Movement Biomarkers
    • 5.2.1 Gait & Mobility Biomarkers
    • 5.2.2 Tremor & Motor Activity Biomarkers
  • 5.3 Speech & Voice Biomarkers
  • 5.4 Oculomotor & Eye Movement Biomarkers
  • 5.5 Neurophysiological Biomarkers
  • 5.6 Sleep & Circadian Rhythm Biomarkers
  • 5.7 Digital Behavioral Biomarkers
  • 5.8 Multimodal Digital Biomarkers
  • 5.9 Other Biomarker Types

6 Global Digital Biomarkers for Neurological Disorders Market, By Neurological Disorder

  • 6.1 Alzheimer's Disease & Other Dementias
  • 6.2 Parkinson's Disease & Movement Disorders
  • 6.3 Multiple Sclerosis
  • 6.4 Epilepsy & Seizure Disorders
  • 6.5 Stroke & Cerebrovascular Disorders
  • 6.6 Amyotrophic Lateral Sclerosis (ALS)
  • 6.7 Huntington's Disease
  • 6.8 Traumatic Brain Injury
  • 6.9 Other Neurological Disorders

7 Global Digital Biomarkers for Neurological Disorders Market, By Technology Platform

  • 7.1 Wearable Sensor-Based Platforms
  • 7.2 Smartphone & Mobile Application-Based Platforms
  • 7.3 Digital Cognitive Assessment Platforms
  • 7.4 Speech & Voice Analysis Platforms
  • 7.5 Eye-Tracking & Computer Vision Platforms
  • 7.6 EEG & Neurophysiological Monitoring Platforms
  • 7.7 Multimodal AI & Digital Biomarker Analytics Platforms
  • 7.8 Other Technology Platforms

8 Global Digital Biomarkers for Neurological Disorders Market, By Clinical Application

  • 8.1 Early Disease Detection & Screening
  • 8.2 Diagnostic Assessment & Clinical Decision Support
  • 8.3 Disease Progression Monitoring
  • 8.4 Symptom Severity & Functional Assessment
  • 8.5 Treatment Response & Therapeutic Monitoring
  • 8.6 Predictive & Prognostic Assessment
  • 8.7 Clinical Trial Digital Endpoints
  • 8.8 Remote Neurological Patient Monitoring
  • 8.9 Other Clinical Applications

9 Global Digital Biomarkers for Neurological Disorders Market, By End User

  • 9.1 Hospitals & Health Systems
  • 9.2 Neurology & Specialty Clinics
  • 9.3 Pharmaceutical & Biotechnology Companies
  • 9.4 Contract Research Organizations
  • 9.5 Academic Medical Centers & Research Institutions
  • 9.6 Home Healthcare & Remote Monitoring Providers
  • 9.7 Diagnostic & Cognitive Assessment Centers
  • 9.8 Other End Users

10 Global Digital Biomarkers for Neurological Disorders Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Koneksa Health, Inc.
  • 13.2 Altoida, Inc.
  • 13.3 Linus Health, Inc.
  • 13.4 Rune Labs, Inc.
  • 13.5 NeuraLight Ltd.
  • 13.6 NeuraMetrix, Inc.
  • 13.7 Neurotrack Technologies, Inc.
  • 13.8 Cambridge Cognition Holdings plc
  • 13.9 Cogstate Ltd.
  • 13.10 IXICO plc
  • 13.11 Aural Analytics, Inc.
  • 13.12 Sonde Health, Inc.
  • 13.13 BioSensics LLC
  • 13.14 Empatica Inc.
  • 13.15 Cumulus Neuroscience Ltd.
  • 13.16 Beacon Biosignals, Inc.
  • 13.17 Huma Therapeutics Limited
  • 13.18 F. Hoffmann-La Roche Ltd.
Product Code: SMRC40922

List of Tables

  • Table 1 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Biomarker Type (2023-2034) ($MN)
  • Table 3 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Cognitive & Neuropsychological Biomarkers (2023-2034) ($MN)
  • Table 4 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Motor Function & Movement Biomarkers (2023-2034) ($MN)
  • Table 5 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Gait & Mobility Biomarkers (2023-2034) ($MN)
  • Table 6 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Tremor & Motor Activity Biomarkers (2023-2034) ($MN)
  • Table 7 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Speech & Voice Biomarkers (2023-2034) ($MN)
  • Table 8 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Oculomotor & Eye Movement Biomarkers (2023-2034) ($MN)
  • Table 9 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Neurophysiological Biomarkers (2023-2034) ($MN)
  • Table 10 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Sleep & Circadian Rhythm Biomarkers (2023-2034) ($MN)
  • Table 11 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Digital Behavioral Biomarkers (2023-2034) ($MN)
  • Table 12 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Multimodal Digital Biomarkers (2023-2034) ($MN)
  • Table 13 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Other Biomarker Types (2023-2034) ($MN)
  • Table 14 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Neurological Disorder (2023-2034) ($MN)
  • Table 15 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Alzheimer's Disease & Other Dementias (2023-2034) ($MN)
  • Table 16 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Parkinson's Disease & Movement Disorders (2023-2034) ($MN)
  • Table 17 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Multiple Sclerosis (2023-2034) ($MN)
  • Table 18 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Epilepsy & Seizure Disorders (2023-2034) ($MN)
  • Table 19 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Stroke & Cerebrovascular Disorders (2023-2034) ($MN)
  • Table 20 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Amyotrophic Lateral Sclerosis (ALS) (2023-2034) ($MN)
  • Table 21 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Huntington's Disease (2023-2034) ($MN)
  • Table 22 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Traumatic Brain Injury (2023-2034) ($MN)
  • Table 23 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Other Neurological Disorders (2023-2034) ($MN)
  • Table 24 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Technology Platform (2023-2034) ($MN)
  • Table 25 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Wearable Sensor-Based Platforms (2023-2034) ($MN)
  • Table 26 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Smartphone & Mobile Application-Based Platforms (2023-2034) ($MN)
  • Table 27 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Digital Cognitive Assessment Platforms (2023-2034) ($MN)
  • Table 28 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Speech & Voice Analysis Platforms (2023-2034) ($MN)
  • Table 29 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Eye-Tracking & Computer Vision Platforms (2023-2034) ($MN)
  • Table 30 Global Digital Biomarkers for Neurological Disorders Market Outlook, By EEG & Neurophysiological Monitoring Platforms (2023-2034) ($MN)
  • Table 31 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Multimodal AI & Digital Biomarker Analytics Platforms (2023-2034) ($MN)
  • Table 32 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Other Technology Platforms (2023-2034) ($MN)
  • Table 33 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Clinical Application (2023-2034) ($MN)
  • Table 34 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Early Disease Detection & Screening (2023-2034) ($MN)
  • Table 35 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Diagnostic Assessment & Clinical Decision Support (2023-2034) ($MN)
  • Table 36 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Disease Progression Monitoring (2023-2034) ($MN)
  • Table 37 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Symptom Severity & Functional Assessment (2023-2034) ($MN)
  • Table 38 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Treatment Response & Therapeutic Monitoring (2023-2034) ($MN)
  • Table 39 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Predictive & Prognostic Assessment (2023-2034) ($MN)
  • Table 40 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Clinical Trial Digital Endpoints (2023-2034) ($MN)
  • Table 41 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Remote Neurological Patient Monitoring (2023-2034) ($MN)
  • Table 42 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Other Clinical Applications (2023-2034) ($MN)
  • Table 43 Global Digital Biomarkers for Neurological Disorders Market Outlook, By End User (2023-2034) ($MN)
  • Table 44 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Hospitals & Health Systems (2023-2034) ($MN)
  • Table 45 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Neurology & Specialty Clinics (2023-2034) ($MN)
  • Table 46 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)
  • Table 47 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Contract Research Organizations (2023-2034) ($MN)
  • Table 48 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Academic Medical Centers & Research Institutions (2023-2034) ($MN)
  • Table 49 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Home Healthcare & Remote Monitoring Providers (2023-2034) ($MN)
  • Table 50 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Diagnostic & Cognitive Assessment Centers (2023-2034) ($MN)
  • Table 51 Global Digital Biomarkers for Neurological Disorders Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!